A population screening programme for atrial fibrillation: A report from the Belgian Heart Rhythm Week screening programme

Europace

Volumn 18, Issue 12, 2016, Pages 1779-1786

  Proietti, Marco ^a   Mairesse, Georges H ^b   Goethals, Peter ^c   Scavee, Christophe ^d   Vijgen, Johan ^e   Blankoff, Ivan ^f   Vandekerckhove, Yves ^g   Lip, Gregory Y H ^a,h  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Clinique du Sud Luxembourg   (Belgium)

^c Saint Jean Clinic of Brussels   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e Jessa Ziekenhuis   (Belgium)

^f Centre Hospitalier Universitaire de Charleroi   (Belgium)

^g Algemene Ziekenhuis St Jan   (Belgium)

^h AALBORG UNIVERSITY   (Denmark)

Author keywords

Atrial fibrillation; Prevalence; Risk factors; Screening

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CHADS2 SCORE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEART RHYTHM; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; VASCULAR DISEASE; BELGIUM; CLINICAL TRIAL; COMPLICATION; DEVICES; DIABETIC COMPLICATION; ELECTROCARDIOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PROCEDURES; RISK FACTOR; STATISTICAL MODEL; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BELGIUM; DIABETES COMPLICATIONS; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 85007620109     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euw069     Document Type: Article

References (27)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2014;131:e29-322.
2. Xiong Q, Proietti M, Senoo K, Lip GYH. Asymptomatic versus symptomatic atrial fibrillation: a systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol 2015;191:172-7.
3. Sanna T, Diener H-C, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478-86.
4. Sposato LA, Cipriano LE, Saposnik G, Vargas ER, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015;14:377-87.
5. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
6. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213-22.
7. Hobbs FDR, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9:iii-iv, ix-x, 1-74.
8. Kaasenbrood F, Hollander M, Rutten FH, Gerhards LJ, Hoes AW, Tieleman RG. Yield of screening for atrial fibrillation in primary care with a hand-held, singlelead electrocardiogram device during influenza vaccination. Europace 2016, pii: euv426 [Epub ahead of print].
9. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: the SEARCH-AF study. Thromb Haemost 2014;111:1167-76.
10. Claes N, Van Laethem C, Goethals M, Goethals P, Mairesse G, Schwagten B et al. Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol 2012;67:273-8.
11. Lip GYH, Lane DA. Stroke prevention in atrial fibrillation. JAMA 2015;313:1950-62.
12. Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A et al. Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace 2009;11:1362-8.
13. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
14. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
15. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med 2013;274:461-8.
16. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-47.
17. Lip GYH, Laroche C, Dan G-A, Santini M, Kalarus Z, Rasmussen LH et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014;16:308-19.
18. Lip GYH, Laroche C, Boriani G, Cimaglia P, Dan G-A, Santini M et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace 2015;17:24-31.
19. Fitzmaurice DA, Hobbs FDR, Jowett S, Mant J, Murray ET, Holder R et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383.
20. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP Study. Circulation 2015;131:2176-84.
21. Vestergaard AS, Ehlers LH. A health economic evaluation of stroke prevention in atrial fibrillation: guideline adherence versus the observed treatment strategy prior to 2012 in Denmark. Pharmacoeconomics 2015;33:967-79.
22. Raparelli V, Proietti M, Buttá C, Di Giosia P, Sirico D, Gobbi P et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med 2014;9:861-70.
23. Kakkar AK, Mueller I, Bassand J-P, Fitzmaurice DA, Goldhaber SZ, Goto S et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013;8:e63479.
24. Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan G-A et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace 2015;17:1777-86.
25. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand S-LT, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006;332:141-5.
26. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011;40:675-83.
27. Proietti M, Lip GYH. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J - Cardiovasc Pharmacother 2015;1:150-2.